Alembic Pharma gets USFDA nod for anti-depression drug 

The approval is for strengths of 75 mg and 100 mg.

Published: 11th June 2018 11:23 AM  |   Last Updated: 11th June 2018 11:23 AM   |  A+A-

Pill, medicine, purpose, tablet, pixabay

Representational image


NEW DELHI: Alembic Pharmaceuticals has received the US health regulator's nod for Bupropion Hydrochloride tablets, used for treatment of major depressive disorder.

"The company has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Bupropion Hydrochloride tablets," Alembic Pharmaceuticals said in a BSE filing.

The approval is for strengths of 75 mg and 100 mg.

The approved product is therapeutically equivalent to the reference listed drug product (RLD) Wellbutrin tablets of GlaxoSmithKline LLC.

Quoting IMS December 2017 data, the company said Bupropion Hydrochloride tablets had an estimated market size of USD 37 million.

The company now has a total of 72 ANDA approvals from the USFDA.

The stock was trading at Rs 467.40 apiece, up 7.49 per cent, on the BSE.


Stay up to date on all the latest Health news with The New Indian Express App. Download now


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp